AstraZeneca retires Medimmune name amid sales turnaround
WEBFeb 14, 2019 · After 30 years of drug development, MedImmune will cease to exist as an industry name now that owner AstraZeneca has decided to retire the brand as part of ongoing restructuring efforts.
MedImmune Receives FDA Approval for Self-Administered Flu …
WEB4 days ago · By Connor Hart. AstraZeneca's MedImmune has received Food and Drug Administration approval for FluMist, an influenza vaccine that can be administered either by oneself or by a healthcare provider ...
MedImmune - Wikipedia
WEBUnder the contract with HHS, MedImmune will continue to make its seasonal FluMist vaccine and also develop a vaccine targeted specifically at the novel H1N1 virus. [5] MedImmune then won a second contract to test its nasal spray flu technology as a viable treatment for the H1N1. [11]
Press Release: AstraZeneca to acquire MedImmune
WEBApr 23, 2007 · MedImmune adds an exciting existing pipeline, including 2 late-stage products, great expertise in biologic drug development and state of the art manufacturing facilities.
AstraZeneca near deal to buy MedImmune - WSJ | Reuters
WEBBritain's AstraZeneca Plc <AZN.L> is near a deal to buy U.S. biotechnology company MedImmune Inc. <MEDI.O> in a transaction that could be worth more than $13 billion, the Wall Street Journal...
AstraZeneca oncology portfolio strengthened as MedImmune
WEBOct 15, 2013 · AstraZeneca today announced that MedImmune, its global biologics research and development arm, has acquired Spirogen, a privately-held biotech company focused on antibody-drug conjugate...
MedImmune to create stand-alone company for early-stage …
WEBFeb 28, 2018 · AstraZeneca today announced that its global biologics research and development arm, MedImmune, is spinning out six molecules from its early-stage inflammation and autoimmunity programmes into an …
MedImmune completes $500m acquisition of Amplimmune
WEBOct 8, 2013 · AstraZeneca's global biologics research and development arm, MedImmune, has completed its acquisition of Amplimmune, in a deal worth up to US $500 million. Amplimmune is a US-based biologics...
Medimmune'in(Licenses'cancer'immunotherapy'tremelimumab'from ... - Pfizer
WEBOct 3, 2011 · MedImmune, the global biologics arm of AstraZeneca, today announced execution of an in-licensing agreement with Pfizer Inc for tremelimumab (CP-675,206), a CTLA-4 monoclonal antibody.
AstraZeneca spins out new biotech, shedding autoimmune drugs
WEBFeb 28, 2018 · MedImmune, AstraZeneca plc’s biologics R&D unit, will spin out six experimental drugs into a standalone biotech, aiming to speed development of assets that fall outside of its core areas of research.
Skip to content